Queen Mary University of London seeks to advance AI for drug discovery

Full Article
Queen Mary University of London seeks to advance AI for drug discovery

Queen Mary University of London has initiated a collaborative research project with AstraZeneca to enhance artificial intelligence applications in drug discovery. This project, led by Professor Greg Slabaugh, aims to develop algorithms for integrating various omic data types, including RNA and protein data. The focus is on expediting the drug discovery process by leveraging AstraZeneca's extensive datasets and Queen Mary's machine learning expertise.

The collaboration seeks to create new analytical capabilities that streamline the drug development pipeline, potentially reducing the time and costs associated with bringing new drugs to market. With the project set to begin in January 2025 and last for 30 months, it represents a significant step towards utilizing AI to transform the pharmaceutical landscape. The partnership highlights the importance of combining academic research with industry data to drive innovation in healthcare.

• Collaboration aims to accelerate drug discovery using AI and multimodal data integration.

• AI tools developed will streamline the drug development process and reduce costs.

Key AI Terms Mentioned in this Article

Multimodal Data Integration

This term refers to algorithms that combine various types of biological data to enhance analysis and insights.

Omics Technologies

Omics technologies involve studying different biological data types, such as genomics and proteomics, to understand complex biological systems.

Companies Mentioned in this Article

Queen Mary University of London

Queen Mary University of London is involved in advancing AI research for drug discovery through academic expertise.

AstraZeneca

AstraZeneca collaborates with Queen Mary to utilize its multi-omic datasets for enhancing drug discovery processes.

Get Email Alerts for AI News

By creating an email alert, you agree to AIleap's Terms of Service and Privacy Policy. You can pause or unsubscribe from email alerts at any time.

Latest Articles

Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive
TechCrunch 6month

Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600

AI In Education - Up-level Your Teaching With AI By Cloning Yourself
Forbes 6month

How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.

Trump's Third Term - How AI Can Help To Overthrow The US Government
Forbes 6month

Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.

Sam Altman Says OpenAI Will Release an 'Open Weight' AI Model This Summer
Wired 6month

Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.

Popular Topics